Chromosome 13q deletion and IgH abnormalities may be both masked by near-tetraploidy in a high proportion of multiple myeloma patients: A combined morphology and I-FISH analysis

Cancer Letters

Volumn 255, Issue 2, 2007, Pages 307-314

  Koren Michowitz, Maya ^a,b   Hardan, Izhar ^a,b   Berghoff, Janina ^a,b   Yshoev, Galina ^a,b   Amariglio, Ninette ^a,b   Rechavi, Gideon ^a,b   Nagler, Arnon ^a,b   Trakhtenbrot, Luba ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

I FISH; Multiple myeloma; Near tetraploidy

Indexed keywords

IMMUNOGLOBULIN HEAVY CHAIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CELL STRUCTURE; CHROMOSOME 13Q; CHROMOSOME 13Q DELETION; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CYTOGENETICS; DISEASE COURSE; DNA DETERMINATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE LOCUS; GENETIC MARKER; HUMAN; HUMAN CELL; INTERPHASE FLUORESCENCE IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PLASMA CELL; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; TETRAPLOIDY;

ADULT; AGED; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 13; FEMALE; GENES, IMMUNOGLOBULIN HEAVY CHAIN; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PLASMA CELLS; POLYPLOIDY;

EID: 34547956265     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.05.005     Document Type: Article

References (27)

1. Sawyer J.R., Waldron J.A., Jagannath S., and Barlogie B. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet. Cytogenet. 82 (1995) 41-49
2. Seong C., Delasalle K., Hayes K., Weber D., Dimopoulos M., Swantkowski J., Huh Y., Glassman A., Champlin R., and Alexander R. Prognostic value of cytogenetics in multiple myeloma. Br. J. Haematol. 101 (1998) 189-194
3. Tricot G., Sawyer J.R., Jagannath S., Desikan K.R., Siegel D., Naucke S., Mattox S., Bracy D., Munshi N., and Barlogie B. Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. J. Clin. Oncol. 15 (1997) 2659-2666
4. Pratt G. Molecular aspects of multiple myeloma. J. Clin. Pathol. 55 (2002) 273-283
5. Debes-Marun C.S., Dewald G.W., Bryant S., Picken E., Santana-Davila R., Gonzalez-Paz N., Winkler J.M., Kyle R.A., Gertz M.A., Witzig T.E., Dispenzieri A., Lacy M.Q., Rajkumar S.V., Lust J.A., Greipp P.R., and Fonseca R. Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia 17 (2003) 427-436
6. Fonseca R., Debes-Marun C.S., Picken E.B., Dewald G.W., Bryant S.C., Winkler J.M., Blood E., Oken M.M., Santana-Davila R., Gonzalez-Paz N., Kyle R.A., Gertz M.A., Dispenzieri A., Lacy M.Q., and Greipp P.R. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood 1 (2003) 2563-2567
7. Smadja N.V., Bastard C., Brigaudeau C., Leroux D., and Fruchart C. Groupe Francais de Cytogenetique Hematologique. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 98 (2001) 2229-2238
8. Fassas A.B., Spencer T., Sawyer J., Zangari M., Lee C.K., Anaissie E., Muwalla F., Morris C., Barlogie B., and Tricot G. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br. J. Haematol. 118 (2002) 1041-1047
9. Nilsson T., Lenhoff S., Turesson I., Rylander L., Mitelman F., Westin J., Hoglund M., and Johansson B. Cytogenetic features of multiple myeloma: impact of gender, age, disease phase, culture time, and cytokine stimulation. Eur. J. Haematol. 68 (2002) 345-353
10. Konigsberg R., Zojer N., Ackermann J., Kromer E., Kittler H., Fritz E., Kaufmann H., Nosslinger T., Riedl L., Gisslinger H., Jager U., Simonitsch I., Heinz R., Ludwig H., Huber H., and Drach J. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma. J. Clin. Oncol. 18 (2000) 804-812
11. Kaufmann H., Kromer E., Nosslinger T., Weltermann A., Ackermann J., Reisner R., Bernhart M., and Drach J. Both chromosome 13 abnormalities by metaphase cytogenetics and deletion of 13q by interphase FISH only are prognostically relevant in multiple myeloma. Eur. J. Haematol. 71 (2003) 179-183
12. Huang S.Y., Yao M., Tang J.L., Tsay W., Lee F.V., Liu M.C., Wang C.H., Chen Y.C., Shen M.C., and Tien H.F. Clinical significance of cytogenetics and interphase fluorescence in situ hybridization analysis in newly diagnosed multiple myeloma in Taiwan. Ann. Oncol. 16 (2005) 1530-1538
13. Hardan I., Rothman R., Gelibter A., Cohen N., Shimoni A., Sokolovsky M., Reichart M., Ishoev G., Amariglio N., Rechavi G., Nagler A., and Trakhtenbrot L. Determination of chromosome 13 status in bone marrow cells of patients with multiple myeloma using combined morphologic and fluorescence in situ hybridization analysis. Exp. Hematol. 32 (2004) 254-260
14. Slovak M.L., Bedell V., Pagel K., Chang K.L., Smith D., and Somlo G. Targeting plasma cells improves detection of cytogenetic aberrations in multiple myeloma: phenotype/genotype fluorescence in situ hybridization. Cancer Genet. Cytogenet. 158 (2005) 99-109
15. Kaplinsky C., Trakhtenbrot L., Hardan I., Reichart M., Daniely M., Toren A., Amariglio N., Rechavi G., and Izraeli S. Tetraploid myeloid cells in donors of peripheral blood stem cells treated with rhG-CSF. Bone Marrow Transplant. 32 (2003) 31-34
16. Cohen N., Novikov I., Hardan I., Esa A., Brok-Simoni F., Amariglio N., Rechavi G., Ben-Bassat I., and Trakhtenbrot L. Standardization criteria for the detection of BCR/ABL fusion in interphase nuclei of chronic myelogenous leukemia patients by fluorescence in situ hybridization. Cancer Genet. Cytogenet. 123 (2000) 102-108
17. Shimoni A., Nagler A., Kaplinsky C., Reichart M., Avigdor A., Hardan I., Daniely M., Zilberstein Y., Amariglio N., Brok-Simoni F., Rechavi G., and Trakhtenbrot L. Chimerism testing and detection of minimal residual disease after allogeneic hematopoietic transplantation using BioView (Duet™) combined morphological and cytological analysis. Leukemia 16 (2002) 1413-1418
18. Trakhtenbrot L., Rechavi G., and Amariglio N. The multiparametric scanning system for evaluation of minimal residual disease in hematological malignancies. Acta Haematol. 112 (2004) 24-29
19. Sen S. Aneuploidy and cancer. Curr. Opin. Oncol. 12 (2000) 82-88
20. Nilsson T., Hoglund M., Lenhoff S., Turesson I., Westin J., Mitelman F., and Johansson B. A pooled analysis of karyotypic patterns, breakpoints and imbalances in 783 cytogenetically abnormal multiple myelomas reveals frequently involved chromosome segments as well as significant age- and sex related differences. Br. J. Haematol. 120 (2003) 960-969
21. Smadja N.V., Leroux D., Soulier J., Arnould C., Taviaux S., Taillemite J.L., and Bastard C. Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases. Genes Chromosomes Cancer 3 (2003) 234-239
22. Pantou D., Rizou H., Tsarouha H., Papanastasiou K., Stamatellou M., Trangas T., Pandis N., and Bardi G. Cytogenetic manifestations of multiple myeloma heterogeneity. Genes Chromosomes Cancer 42 (2005) 44-57
23. Mateo G., Castellanos M., Rasillo A., Gutierrez N.C., Montalban M.A., Martin M.L., Hernandez J.M., Lopes-Berges M.C., Montejano L., Blade J., Mateos M.V., Sureda A., de la Rubina J., Diaz-Mediavilla J., Pandiella A., Lahuerta J.J., Orfao A., and San Miguel J.F. Genetic abnormalities and patterns of antigenic expression in multiple myeloma. Clin. Cancer Res. 11 (2005) 3661-3667
24. Chng W.J., Winkler J.M., Greipp P.R., Jalal S.M., Bergsagel P.L., Chesi M., Trendle M.C., Ahmann G.J., Henderson K., Blood E., Oken M.M., Hulbert A., Van Wier S.A., Santana-Davila R., Kyle R.A., Gertz M.A., Lacy M.Q., Dispenzieri A., and Fonseca R. Ploidy status rarely changes in myeloma patients at disease progression. Leuk. Res. 30 (2006) 266-271
25. Greipp P.R., Lust J.A., O'Fallon W.M., Katzmann J.A., Witzig T.E., and Kyle R.A. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 81 (1993) 3382-3387
26. Rajkumar S.V., Fonseca R., Lacy M.Q., Witzig T.E., Therneau T.M., Kyle R.A., Litzow M.R., Gertz M.A., and Greipp P.R. Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myeloma. J. Clin. Oncol. 17 (1999) 1551-1557
27. Leleu X., Genevieve F., Guieze R., Duhamel A., Andrieux J., Berthon C., Godon A., Prat-Lesaffre S., Depil S., Lai J.L., Facon T., and Zandecki M. Intergroupe Francophone du Myelome (IFM), Irregular nuclear shape of bone marrow plasma cells defines a multiple myeloma subgroup related to hypodiploidy and to short survival. Leuk. Res. 29 (2005) 665-671